Belite Bio, Inc (BLTE)
| Market Cap | 5.63B +181.5% |
| Revenue (ttm) | n/a |
| Net Income | -77.61M |
| EPS | -2.31 |
| Shares Out | 39.34M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 256,534 |
| Open | 149.77 |
| Previous Close | 149.95 |
| Day's Range | 141.34 - 149.95 |
| 52-Week Range | 56.10 - 200.00 |
| Beta | -1.19 |
| Analysts | Strong Buy |
| Price Target | 198.00 (+38.46%) |
| Earnings Date | May 20, 2026 |
About BLTE
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical dev... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for BLTE stock is "Strong Buy." The 12-month stock price target is $198.0, which is an increase of 38.46% from the latest price.
News
Belite Bio Announces Oral Presentation at the 27th Fundus Disease Forum and International Retinal Symposium (Retina China 2026)
SAN DIEGO, May 15, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), (“Belite Bio®” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel th...
Belite Bio Transcript: Bank of America Global Healthcare Conference 2026
The company is advancing tinlarebant, an oral therapy for Stargardt disease, with phase III data showing a 36% reduction in lesion growth and strong physician enthusiasm. Regulatory submissions are underway, with U.S. approval expected within six months and a $7 billion peak sales opportunity projected.
Belite Bio to Host Webcast on May 20, 2026, to Discuss First Quarter 2026 Financial Results
SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), (“Belite Bio®” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel th...
Belite Bio management to meet wit Cantor
Breakfast Meeting to be held in Denver on May 5 hosted by Cantor.
Belite Bio Transcript: Deutsche Bank ADR Virtual Investor Conference
Tinlarebant, an oral therapy for Stargardt disease, achieved a 36% reduction in lesion growth and sustained 80% RBP4 reduction in phase III trials, with strong safety and regulatory progress. The therapy addresses a major unmet need and is positioned for broad application in retinal diseases.
Belite Bio to Present at the Deutsche Bank American Depositary Receipt Virtual Investor Conference on April 28th
SAN DIEGO, April 22, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) a clinical stage development company based in San Diego and focused on advancing novel therapeutics targeting degenerative ...
Belite Bio initiates rolling submission of NDA to U.S FDA for tinlarebant
Belite Bio (BLTE) announced that it has initiated a rolling submission of a New Drug Application, NDA, to the U.S. Food and Drug Administration, FDA, for tinlarebant, an investigational novel…
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage development company focused on advancing novel therapeutics targeting degenerative retinal diseases that ...
Belite Bio Transcript: Leerink Global Healthcare Conference 2026
Tinlarebant, an oral RBP4 antagonist, showed a 36% reduction in Stargardt disease progression in a global phase III trial, with strong safety and efficacy in both eyes. U.S. and global regulatory filings are underway, and commercialization plans focus on genetic testing and market readiness.
Belite Bio price target raised to $200 from $185 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Belite Bio (BLTE) to $200 from $185 and keeps a Buy rating on the shares following the Q4 report. The Phase 3…
Belite Bio price target raised to $266 from $200 at Cantor Fitzgerald
Cantor Fitzgerald raised the firm’s price target on Belite Bio (BLTE) to $266 from $200 and keeps an Overweight rating on the shares. Recent commentary suggested a possibility of a…
Belite Bio price target raised to $217 from $187 at Benchmark
Benchmark raised the firm’s price target on Belite Bio (BLTE) to $217 from $187 and keeps a Buy rating on the shares. The company “achieved a major catalyst” during Q4…
Belite Bio price target raised to $201 from $191 at Morgan Stanley
Morgan Stanley analyst Judah Frommer raised the firm’s price target on Belite Bio (BLTE) to $201 from $191 and keeps an Overweight rating on the shares. The company’s Q4 update…
Belite Bio price target raised to $200 from $195 at BofA
BofA raised the firm’s price target on Belite Bio (BLTE) to $200 from $195 and keeps a Buy rating on the shares. After the company reported FY25 results and provided…
Belite Bio Earnings Call Transcript: Q4 2025
Key 2025 milestones included positive phase III results for Stargardt disease, strong fundraising, and a robust cash position. NDA submission is planned for Q2 2026, with commercialization targeted for Q1 2027 and significant investments in launch preparation.
Belite Bio sees Q4 adjusted EPS (38c), consensus (54c)
“2025 marked a defining year for Belite, highlighted by positive topline results from our pivotal Phase 3 DRAGON trial, establishing tinlarebant as a potential first-in-class therapy for Stargardt dis...
Belite Bio sees FY25 adjusted EPS ($1.15) vs. ($89c) last year
06:11 EST Belite Bio (BLTE) sees FY25 adjusted EPS ($1.15) vs. ($89c) last year
Belite Bio Reports Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
SAN DIEGO, March 02, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targetin...
Belite Bio price target raised to $223 from $194 at Mizuho
Mizuho analyst Graig Suvannavejh raised the firm’s price target on Belite Bio (BLTE) to $223 from $194 and keeps an Outperform rating on the shares.
Belite Bio completes enrollment in DRAGON II trial of tinlarebant
Belite Bio (BLTE) announced the completion of enrollment of 60 subjects, including 15 Japanese subjects, in the Phase 2/3 DRAGON II clinical trial evaluating tinlarebant for the treatment of Stargardt...
Belite Bio initiated with a Buy at BofA
BofA analyst Tazeen Ahmad initiated coverage of Belite Bio (BLTE) with a Buy rating and $195 price target Tinlarebant is an oral, once-daily RPB4 antagonist that has produced positive Phase…
Belite Bio initiated with an Overweight at Morgan Stanley
Morgan Stanley initiated coverage of Belite Bio (BLTE) with an Overweight rating and $191 price target The firm says its key opinion leader checks support a multi-billion dollar opportunity for…
Belite Bio participates in a conference call with H.C. Wainwright
Healthcare Analyst Yi Chen, along with Chief Medical Officer Scholl discuss the company’s reported data from the Phase 3 DRAGON trial of Tinlarebant in adolescent patients with Stargardt disease on…
Belite Bio price target raised to $200 from $140 at Maxim
Maxim raised the firm’s price target on Belite Bio (BLTE) to $200 from $140 and keeps a Buy rating on the shares after the company reported positive topline results from…
Belite Bio 2.273M share Spot Secondary priced at $154.00
The deal range was $150.00-$154.00. Morgan Stanley, Leerink, BofA and Cantor Fitzgerald acted as joint book running managers for the offering.